Exosomes Implication in PD1-PD-L1 Activation in OSAS (ExoSAS)

U

University Hospital, Angers

Status

Completed

Conditions

Sleep Apnea Syndromes, Obstructive
Cancer

Treatments

Diagnostic Test: PD1/PD-L1 exosomal expression

Study type

Observational

Funder types

Other

Identifiers

NCT03811600
2019-A00029-48

Details and patient eligibility

About

An increased occurrence of cancer associated mortality has been described in patients with Obstructive Sleep Apnea Syndrome (OSAS). This association might be partially explained by an impaired cellular immune response that has been described in OSAS. Is has been suggested that OSAS impact immune cells by upregulation of the PD-1/PD-L1 pathway. Exosomes are small membrane vesicles released by numerous cells in the bloodstream. Exosomes have been shown to be implicated in cancer cells proliferation via a PD-1/PD-L1 pathway activation. This study will evaluate exosomal PD-1/PD-L1 expression in patients with OSAS as compared to controls and will further investigate their impact on immune cells function and proliferation capacities.

Enrollment

90 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients requiring a sleep recording for suspected OSAS

Exclusion criteria

  • Préviously treated OSAS
  • Cancer past history
  • Pregnant women
  • Cognitif impairment

Trial design

90 participants in 2 patient groups

OSAS patients
Description:
45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour
Treatment:
Diagnostic Test: PD1/PD-L1 exosomal expression
Non OSAS patients
Description:
45 patients investigated for suspected OSAS with an apnea hypopnea index <15 per hour
Treatment:
Diagnostic Test: PD1/PD-L1 exosomal expression

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems